

# Efficiency of electrochemotherapy in treatment of head and neck cancer

<b>Submission date</b> 04/01/2016	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 07/01/2016	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 18/10/2022	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Electrochemotherapy is a cancer treatment. It works through injection of a chemotherapeutic drug (such as bleomycin) and then applying an electric pulse to send the chemotherapy into the cancer cells. Between 70-80% of tumours respond to this treatment. It is currently used for treating skin cancer in 150 centres throughout Europe. The aim of this study is to test how effective and safe electrochemotherapy is in patients with head and neck cancers and measure the concentration of drug bleomycin in the serum (blood) and in the tumour itself.

### Who can participate?

Adults (aged over 18) with head or neck cancer, that have not had chemotherapy for at least 2 weeks and are expected to live for more than 3 months.

### What does the study involve?

All participants have the electrochemotherapy treatment. The procedure is standardized and is performed according to the published Standard Operating Procedure (SOP) for electrochemotherapy. The chemotherapy drug Bleomycin is injected intravenously (through a needle in a vein) in dose of 15,000 IU/m<sup>2</sup>. After 8 minutes, electric pulses are delivered to the tumour in order to send the bleomycin into the cancer cells. The response of the tumour to the treatment is assessed at one month and again at two months.

### What are the possible benefits and risks of participating?

So far minimal or no side effects have been reported. Due to the pain caused by the electric pulses, local or general anaesthesia will be needed. There may be some reddening of the skin but no pain after the treatment is complete is expected.

### Where is the study run from?

The University Medical Centre Ljubljana and Institute of Oncology Ljubljana (Slovenia)

### When is the study starting and how long is it expected to run for?

July 2015 to December 2017

Who is funding the study?  
Slovenian Research Agency

Who is the main contact?  
1. Professor Gregor Sersa (scientific)  
gsersa@onko-i.si  
2. Mr Ales Groselj (public)  
ales.groselj@kclj.si

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Gregor Sersa

**ORCID ID**  
<http://orcid.org/0000-0002-7641-5670>

**Contact details**  
Institute of Oncology Ljubljana  
Zaloska 2  
Ljubljana  
Slovenia  
1000  
+386 1/5879434  
gsersa@onko-i.si

**Type(s)**  
Scientific

**Contact name**  
Mr Ales Groselj

**Contact details**  
Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre  
Ljubljana,  
Zaloska 2  
Ljubljana  
Slovenia  
1000  
+38615222153  
ales.groselj@kclj.si

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

## Study information

### Scientific Title

Efficiency of electrochemotherapy in treatment of head and neck cancer: a multicentre, interventional study

### Acronym

NECT

### Study objectives

The aim of the study is to evaluate the efficacy and safety of electrochemotherapy with bleomycin and improvement of therapeutic procedures in patients with cancer in head and neck region treated with electrochemotherapy.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Republic of Slovenia National Ethics Committee, 23/06/2015, ref: KME 058/06/15

### Study design

Multicentre interventional study

### Primary study design

Interventional

### Secondary study design

Non randomised study

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

### Health condition(s) or problem(s) studied

Cancer in the head and neck region

### Interventions

All patients are treated with electrochemotherapy with bleomycin, according to European Standard Operating Procedures of Electrochemotherapy. Bleomycin will be injected

intravenously in a dose of 15,000 IU/m<sup>2</sup> skin surface. The electric pulses will be delivered by electrodes to the tumors generated by electric pulse generator Cliniporator (IGEA, Carpi, Italy) 8-28 minutes after bleomycin injection. During the procedure tumor tissue and blood samples will be collected for the purpose of pharmacological analysis. Patients will be followed up at 1, 2, 4, 8, 12, 18 and 24 months after the treatment.

### **Intervention Type**

Procedure/Surgery

### **Primary outcome measure**

1. Antitumor efficiency of electrochemotherapy, evaluated by measurement of tumor response in accordance with RECIST criteria, 1 and 2 months after the treatment
2. Safety of electrochemotherapy. Any adverse events will be recorded according to National Cancer Institute (NCI) criteria

### **Secondary outcome measures**

Setting a time frame of optimal concentration of bleomycin in tumors and plasma for effective electrochemotherapy treatment.

### **Overall study start date**

01/07/2015

### **Completion date**

31/12/2017

## **Eligibility**

### **Key inclusion criteria**

1. Histologically or cytologically confirmed carcinoma and/or recurrent disease and/or multiple nodules on different sites and/or tumors that require reconstruction with the local and / or remote lobes and/or tumors located at the sites where after excision poor aesthetic outcome is expected and/or patients who refuse other treatment options
2. Age over 18
3. The life expectancy more than 3 months
4. Performance status Karnofsky  $\geq 70$  or (World Health Organization) WHO  $\leq 2$
5. Chemotherapy free interval at least 2 weeks
6. Patient must be mentally capable of understanding the information given
7. Patient must give informed consent
8. Patient must be discussed at the multidisciplinary team

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Lower age limit**

18 Years

### **Sex**

Both

**Target number of participants**

50

**Total final enrolment**

78

**Key exclusion criteria**

1. Lesions which are not suitable for treatment with electrochemotherapy (invasion into the bone, infiltration of large vessels)
2. Life-threatening infection and/or heart failure and/or liver failure and/or other severe systemic pathologies
3. Significant reduction in respiratory function
4. Age less than 18 years
5. Coagulation disturbances
6. Cumulative dose of 250 mg/m<sup>2</sup> bleomycin received
7. Allergic reaction to bleomycin
8. Impaired kidney function (creatinin > 150 µmol/l)
9. Patients with epilepsy
10. Pregnancy
11. Patients incapable to understand the aim of the study or those who do not agree with the inclusion

**Date of first enrolment**

01/07/2015

**Date of final enrolment**

30/09/2017

## **Locations**

**Countries of recruitment**

Slovenia

**Study participating centre**

Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre  
Ljubljana  
Zaloska 2  
Ljubljana  
Slovenia  
1000

**Study participating centre**

Institute of Oncology Ljubljana  
Zaloska 2  
Ljubljana

Slovenia  
1000

## Sponsor information

### Organisation

Ljubljana University Medical Centre

### Sponsor details

Clinic of Otorhinolaryngology and Cervicofacial Surgery

Zaloska 2

Ljubljana

Slovenia

1000

### Sponsor type

Hospital/treatment centre

### Website

<http://www.kclj.si/>

### ROR

<https://ror.org/01nr6fy72>

### Organisation

Institute of Oncology Ljubljana

### Sponsor details

Zaloska 2

Ljubljana

Slovenia

1000

### Sponsor type

Hospital/treatment centre

## Funder(s)

### Funder type

Government

### Funder Name

### Alternative Name(s)

Slovenian Research Agency, Javna agencija za raziskovalno dejavnost RS v angleškem jeziku: Slovenian Research Agency, Javna Agencija za Raziskovalno Dejavnost RS, The Slovenian Research and Innovation Agency (ARIS), Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije, ARRS, ARIS

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

Slovenia

## Results and Publications

### Publication and dissemination plan

1. Pharmacological study will be performed in order to determine the optimal therapeutic window for electrochemotherapy (article in preparation)
2. Clinical response data will be collected and analysed, for evaluation of the therapeutic effectiveness of electrochemotherapy in patients with cancer in head and neck region. (article will be prepared at the end of the study)
3. The data of the bleomycin content in tumours at the time of electrochemotherapy will be correlated with the treatment outcome. (article will be prepared at the beginning of 2017)

### Intention to publish date

31/12/2018

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available. The data will be held in an institutional electrochemistry database.

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2016		Yes	No
<a href="#">Protocol file</a>			30/08/2022	No	No
<a href="#">Protocol file</a>			30/08/2022	No	No